Insulin Glargine News and Research RSS Feed - Insulin Glargine News and Research

Comprehensive analysis of China’s insulin glargine market

Comprehensive analysis of China’s insulin glargine market

Research and Markets has announced the addition of the "Investigation Report on China Insulin Glargine Market, 2009-2018" report to their offering. [More]

Merck, Samsung Bioepis agree to develop, commercialize MK-1293 for treatment of diabetes

Merck, known as MSD outside the United States and Canada, and Samsung Bioepis Co., Ltd., announced today that they have expanded their collaboration with an agreement to develop, manufacture and commercialize MK-1293, an insulin glargine candidate for the treatment of patients with type 1 and type 2 diabetes. Phase III clinical studies in type 1 and type 2 diabetes will begin soon. [More]
Eli Lilly's revenue decreases 2% to $5.809 billion in fourth quarter 2013

Eli Lilly's revenue decreases 2% to $5.809 billion in fourth quarter 2013

Eli Lilly and Company today announced financial results for the fourth quarter and full year of 2013. Certain financial information for 2013 and 2012 are presented on both a reported and a non-GAAP basis. [More]
Market research report on injectable generic and biosimilar drugs

Market research report on injectable generic and biosimilar drugs

Reportlinker.com announces that a new market research report is available in its catalogue: Injectable Generic and Biosimilar Drugs - Potential Opportunities for Developers 2013 [More]

Lilly, Boehringer Ingelheim announce FDA acceptance of NDA filing for new insulin glargine product

Eli Lilly and Company and Boehringer Ingelheim today announced that the U.S. Food and Drug Administration has accepted the filing of the New Drug Application for LY2963016, an investigational basal (long-acting) insulin. [More]
Lilly Peers Into Future, Sees Three Drug Launches In 2014

Lilly Peers Into Future, Sees Three Drug Launches In 2014

... [More]
Sanofi reports Phase 3 study of insulin U300 shows better blood sugar control than Lantus

Sanofi reports Phase 3 study of insulin U300 shows better blood sugar control than Lantus

Sanofi announced today that the first Phase 3 study results for its investigational new insulin U300 showed equivalent blood sugar control with fewer night-time low blood sugar events compared to Lantus. [More]
Insulin degludec has reduced risk of recurrent hypoglycemia than insulin glargine

Insulin degludec has reduced risk of recurrent hypoglycemia than insulin glargine

Insulin degludec (Tresiba), a new ultra-long-acting insulin, has a similar or reduced risk of recurrent hypoglycemia—low blood sugar—compared with the commercially available insulin glargine, a new meta-analysis study finds. [More]

Eli Lilly reports positive results from Phase III AWARD trials of type 2 diabetes drug, dulaglutide

Eli Lilly and Company today announced positive top-line results of two additional Phase III AWARD trials for dulaglutide, an investigational, long-acting glucagon-like peptide 1 (GLP-1) receptor agonist being studied as a once-weekly treatment for type 2 diabetes. [More]

Insulin degludec shows promise in diabetes

Self-administration of daily insulin degludag injections is no less effective than self-injecting insulin glargine in patients with diabetes who are new to insulin therapy, say researchers. [More]
Boehringer Ingelheim, Lilly announce data from LY2605541 Phase II study on type 2 diabetes

Boehringer Ingelheim, Lilly announce data from LY2605541 Phase II study on type 2 diabetes

Eli Lilly and Company and Boehringer Ingelheim today announced patient-reported health outcomes data from a Phase II study of their investigational novel basal insulin analogue, LY2605541, in patients with type 2 diabetes. [More]
GW to evaluate effectiveness of glucose-lowering drugs against type 2 diabetes

GW to evaluate effectiveness of glucose-lowering drugs against type 2 diabetes

John Lachin, professor of biostatistics, epidemiology and statistics at the George Washington University, has been awarded a five-year, $134 million grant from the National Institute of Health's National Institute of Diabetes and Digestive and Kidney Diseases to conduct a clinical trial examining the long-term effectiveness of several glucose-lowering medications for treatment of people with type 2 diabetes. The grant sets a record as the largest sum award GW has ever received. [More]

Biodel initiates BIOD-123 Phase 2 trial in Type 1 diabetes

Biodel Inc. today announced the initiation of a Phase 2 clinical trial of its proprietary recombinant insulin (RHI)-based ultra-rapid-acting mealtime insulin candidate, BIOD-123. [More]
Insulin glargine retards progression of atherosclerosis in high-risk people

Insulin glargine retards progression of atherosclerosis in high-risk people

A sub-study of the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial, designed to investigate the effect of insulin glargine and omega-3 fatty acids on atherosclerosis progression, has found that, compared to standard care, only insulin glargine (a long-acting insulin) had a "modest" statistically non-significant reducing effect on the primary outcome of rate of change in maximum carotid intima media thickness (CIMT) at 12 carotid sites. [More]
Lilly, Boehringer Ingelheim receive FDA approval for Tradjenta sNDA to treat type 2 diabetes

Lilly, Boehringer Ingelheim receive FDA approval for Tradjenta sNDA to treat type 2 diabetes

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for Tradjenta (linagliptin) tablets for use as add-on therapy to insulin. [More]

Degludec reduces risk of nighttime low blood sugar in elderly diabetic adults

A new variety of long-lasting insulin, called insulin degludec, lowers the risk of nighttime low blood sugar in elderly diabetic adults compared with insulin glargine, a systematic review of diabetes studies has found. [More]

Insulin more effective add-on than sitagliptin in glucose control

Insulin seems to be a more effective add-on regimen than sitagliptin in patients with diabetes inadequately controlled by metformin monotherapy, show study findings. [More]
Sanofi’s insulin glargine delays progression from pre-diabetes to T2DM

Sanofi’s insulin glargine delays progression from pre-diabetes to T2DM

Sanofi presented results from the landmark ORIGIN trial (Outcome Reduction with Initial Glargine Intervention) at the American Diabetes Association 72nd Scientific sessions. The key findings showed that, compared to standard care, Lantus(insulin glargine [rDNA] injection) had no statistically significant positive or negative impact on cardiovascular (CV) outcomes versus standard care during the study period and that there was no association between insulin glargine use and increased risk of any cancer. [More]
Long-term insulin use does not increase risk of heart disease in people with diabetes

Long-term insulin use does not increase risk of heart disease in people with diabetes

Researchers at McMaster University have discovered that long-term insulin use does not harm people with diabetes or pre-diabetes or put them at risk of heart attacks, strokes or cancer. [More]

Sanofi’s Lantus more effective than sitagliptin for people with type 2 diabetes

Sanofi announced today that people with early type 2 diabetes uncontrolled on metformin demonstrated superior HbA1c - glycated hemoglobin - reduction with Lantus (insulin glargine [rDNA origin] injection) versus sitagliptin. [More]